Étude NCT03445533 : étude de phase 3 comparant l’efficacité du tilsotolimod associé à de l’ipilimumab par rapport à celle de l’ipilimumab seul chez des patients ayant un mélanome réfractaire au traitement par anti-PD1. Le mélanome est une tumeur maligne qui prend naissance dans les cellules de la peau, les mélanocytes. Un changement de la couleur, de la taille ou de la forme d’un grain de beauté est souvent le premi...

• Country France
• organs Mélanomes cutanés
• Specialty Immunothérapie - Vaccinothérapie

A Phase 2 Study of IMO-8400 in Patients with Dermatomyositis • To assess the safety and tolerability of IMO-8400 in adult patients with dermatomyositis (DM) with active skin and muscle disease • To assess the effect of IMO-8400 on the cutaneous manifestations o...

• Country None
• organs None
• Specialty None

12-week Trial of IMO-2125 plus Ribavirin in Patients Infected with Hepatitis C Virus who have never before received any treatment for this infection To evaluate the safety and tolerability of different dosages of a 12-week course of IMO-2125 plus ribavirin compared to peg-rIFN plus ribavirin administered to treatment-naïve patients with chronic HC...

• Country None
• organs None
• Specialty None

A study with IMO-8400 in Patients with Moderate to Severe Psoriasis Evaluation of safety and tolerability of different dose levels of IMO-8400 compared with placebo administered for 12 weeks

• Country None
• organs None
• Specialty None

A Multi-center, Randomized, Double-blind, Comparator-controlled, Dose-escalation Safety Assessment Study of Combination Treatment with IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients Assessment of the safety and tolerability of different dosages of IMO-2125 in combination with standard ribavirin compared to placebo and ribavirin or to Pegasys plus ribavirin.

• Country None
• organs None
• Specialty None

A Phase 2, Randomized, Double-Blind, Comparator-Controlled, 12-week Trial of IMO-2125 plus Ribavirin in Patients Infected with Hepatitis C Virus who were Nonresponders to Pegylated-Interferon plus Ribavirin To evaluate the safety and tolerability of different regimens of IMO-2125 in combination with ribavirin compared to PegasysTM plus ribavirin administered for 12 weeks to patients with chronic HCV infe...

• Country None
• organs None
• Specialty None